Tejas Patil
University of Colorado Cancer Center · 184 works · 3,802 citations · h-index 26
Top works
- Non–Small Cell Lung Cancer, Version 4.2024
- Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
- NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
- The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
- 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
- Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation
- A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics
- ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
- Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
- NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
- Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
- Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
- Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status
- Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
- Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients
- Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
- Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
- NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.